STAT

Plastic tubes can’t save the lives of liver failure patients, and a biotech’s stock price plummets

Another effort by Vital Therapies to transform plastic tubes into a lifesaving artificial liver ended in disappointment.

Another effort by Vital Therapies () to transform into a lifesaving artificial liver ended in disappointment Wednesday. And after this latest setback, the

You're reading a preview, sign up to read more.

More from STAT

STAT1 min readPsychology
Acadia Pharma Drug Fails To Improve Psychosis In Schizophrenia Patients
A plan to expand the use of Acadia Pharmaceuticals’ only approved medicine to cover the treatment of patients with schizophrenia was dealt a setback with the failure of a late-stage…
STAT5 min readSociety
What The Ebola Emergency Means, What It Doesn’t Mean, And What’s Next
Finally, the WHO has declared the world’s latest Ebola outbreak a global health emergency. But what, exactly, does that mean?
STAT5 min readScience
The Superbug Candida Auris Is Giving Rise To Warnings — and Big Questions
STAT asked scientists to describe what they see as the most pressing research questions about Candida auris, a feared superbug. The list is long.